Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study
Conclusions:
In this short-term treatment study, 10 weeks of liraglutide treatment had no significant effect on neither coronary nor peripheral microvascular function in patients with type 2 diabetes. Further long-term studies, preferably in patients with more impaired microvascular function and using a higher dosage of GLP-1 analogues, are needed to confirm these findings.Trial registrationClinicalTrials.gov: NCT01931982.
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Rebekka FaberMette ZanderAdam PenaMarie MichelsenNaja MygindEva Prescott Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Study | Victoza